Current and future role of neoadjuvant therapy for breast cancer

被引:188
作者
Untch, Michael [1 ]
Konecny, Gottfried E. [2 ]
Paepke, Stefan [3 ]
von Minckwitz, Gunter [4 ,5 ]
机构
[1] HELIOS Klinikum Berlin Buch, Dept Gynecol, D-13125 Berlin, Germany
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA
[3] Tech Univ Munich, Klinikum Rechts Isar, Ob Gyn, Interdisciplinary Breast Ctr, D-80290 Munich, Germany
[4] GBG Forsch GmbH, German Breast Grp, Neu Isenburg, Germany
[5] Univ Womens Hosp, Frankfurt, Germany
关键词
Breast cancer; Molecular subtypes; Neoadjuvant systemic therapy; Pathologic complete response; Breast conserving surgery; SURGICAL ADJUVANT BREAST; PATHOLOGICAL COMPLETE REMISSION; PREOPERATIVE CHEMOTHERAPY; OPEN-LABEL; AROMATASE INHIBITOR; FOLLOW-UP; TRASTUZUMAB; WOMEN; TRIAL; MULTICENTER;
D O I
10.1016/j.breast.2014.06.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Neoadjuvant systemic chemotherapy is a possible therapeutic approach for the treatment of locally advanced operable, primarily non-operable or inflammatory breast cancer. Neoadjuvant systemic chemotherapy is an option for breast cancer patients who would require adjuvant chemotherapy otherwise based on clinical and histological examination and imaging. The use of neoadjuvant systemic therapy in operable breast cancer is currently increasing because of its advantages that include higher rates of breast conserving surgery and the possibility of measuring early in-vivo response to systemic treatment. The timing of axillary sentinel lymph node diagnosis (i.e. before or after neoadjuvant chemotherapy) is critical in that it may influence the likelihood of axillary preservation. It is not yet clear if neoadjuvant therapy might improve outcomes in certain subgroups of breast cancer patients. Neoadjuvant treatment modalities require a close collaboration between oncology professionals, including surgeons, gynecologists, medical oncologists, radiation oncologists, radiologists and pathologists. The most important parameter for treatment success and improved overall survival is the achievement of a pathologic complete response (pCR), although the role of pCR in patients with luminal A like tumours might be less informative. Identification of patient subgroups with high pCR rates may allow less invasive surgical or radiological interventions. Patients not achieving a pCR may be candidates for postoperative clinical trials exploring novel systemic treatments. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:526 / 537
页数:12
相关论文
共 59 条
[1]  
Allis S, 2012, TUMORI J, V98, P543, DOI 10.1700/1190.13193
[2]   Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial [J].
Baselga, Jose ;
Bradbury, Ian ;
Eidtmann, Holger ;
Di Cosimo, Serena ;
de Azambuja, Evandro ;
Aura, Claudia ;
Gomez, Henry ;
Dinh, Phuong ;
Fauria, Karine ;
Van Dooren, Veerle ;
Aktan, Gursel ;
Goldhirsch, Aron ;
Chang, Tsai-Wang ;
Horvath, Zsolt ;
Coccia-Portugal, Maria ;
Domont, Julien ;
Tseng, Ling-Min ;
Kunz, Georg ;
Sohn, Joo Hyuk ;
Semiglazov, Vladimir ;
Lerzo, Guillermo ;
Palacova, Marketa ;
Probachai, Volodymyr ;
Pusztai, Lajos ;
Untch, Michael ;
Gelber, Richard D. ;
Piccart-Gebhart, Martine .
LANCET, 2012, 379 (9816) :633-640
[3]   Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer [J].
Baselga, Jose ;
Semiglazov, Vladimir ;
van Dam, Peter ;
Manikhas, Alexey ;
Bellet, Meritxell ;
Mayordomo, Jose ;
Campone, Mario ;
Kubista, Ernst ;
Greil, Richard ;
Bianchi, Giulia ;
Steinseifer, Jutta ;
Molloy, Betty ;
Tokaji, Erika ;
Gardner, Humphrey ;
Phillips, Penny ;
Stumm, Michael ;
Lane, Heidi A. ;
Dixon, J. Michael ;
Jonat, Walter ;
Rugo, Hope S. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) :2630-2637
[4]  
Bauerfeind I, 2014, NEOADJUVANT PRIMARY
[5]   Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer [J].
Bear, Harry D. ;
Tang, Gong ;
Rastogi, Priya ;
Geyer, Charles E., Jr. ;
Robidoux, Andre ;
Atkins, James N. ;
Baez-Diaz, Luis ;
Brufsky, Adam M. ;
Mehta, Rita S. ;
Fehrenbacher, Louis ;
Young, James A. ;
Senecal, Francis M. ;
Gaur, Rakesh ;
Margolese, Richard G. ;
Adams, Paul T. ;
Gross, Howard M. ;
Costantino, Joseph P. ;
Swain, Sandra M. ;
Mamounas, Eleftherios P. ;
Wolmark, Norman .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (04) :310-320
[6]   Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 [J].
Bear, HD ;
Anderson, S ;
Smith, RE ;
Geyer, CE ;
Mamounas, EP ;
Fisher, B ;
Brown, AM ;
Robidoux, A ;
Margolese, R ;
Kahlenberg, MS ;
Paik, S ;
Soran, A ;
Wickerham, DL ;
Wolmark, N .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) :2019-2027
[7]   Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer The ACOSOG Z1071 (Alliance) Clinical Trial [J].
Boughey, Judy C. ;
Suman, Vera J. ;
Mittendorf, Elizabeth A. ;
Ahrendt, Gretchen M. ;
Wilke, Lee G. ;
Taback, Bret ;
Leitch, A. Marilyn ;
Kuerer, Henry M. ;
Bowling, Monet ;
Flippo-Morton, Teresa S. ;
Byrd, David R. ;
Ollila, David W. ;
Julian, Thomas B. ;
McLaughlin, Sarah A. ;
McCall, Linda ;
Symmans, W. Fraser ;
Le-Petross, Huong T. ;
Haffty, Bruce G. ;
Buchholz, Thomas A. ;
Nelson, Heidi ;
Hunt, Kelly K. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (14) :1455-1461
[8]   Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation [J].
Buchholz, TA ;
Tucker, SL ;
Masullo, L ;
Kuerer, HM ;
Erwin, J ;
Salas, J ;
Frye, D ;
Strom, EA ;
McNeese, MD ;
Perkins, G ;
Katz, A ;
Singletary, SE ;
Hunt, KK ;
Buzdar, AU ;
Hortobagyi, GN .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :17-23
[9]   Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer [J].
Buzdar, AU ;
Ibrahim, NK ;
Francis, D ;
Booser, DJ ;
Thomas, ES ;
Theriault, RL ;
Pusztai, L ;
Green, MC ;
Arun, BK ;
Giordano, SH ;
Cristofanilli, M ;
Frye, DK ;
Smith, TL ;
Hunt, KK ;
Singletary, SE ;
Sahin, AA ;
Ewer, MS ;
Buchholz, TA ;
Berry, D ;
Hortobagyi, GN .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :3676-3685
[10]   Breast conservation after neoadjuvant chemotherapy: The M.D. Anderson Cancer Center experience [J].
Chen, AM ;
Meric-Bernstam, F ;
Hunt, KK ;
Thames, HD ;
Oswald, MJ ;
Outlaw, ED ;
Strom, EA ;
McNeese, MD ;
Kuerer, HM ;
Ross, MI ;
Singletary, SE ;
Ames, FC ;
Feig, BW ;
Sahin, AA ;
Perkins, GH ;
Schechter, NR ;
Hortobagyi, GN ;
Buchholz, TA .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2303-2312